Business
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European...
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily
About this update from Bioatla, Inc.
[{"type":"text","content":"BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting \n An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores ozuriftamab vedotin’s activity in a high unmet need SCCHN patient population The conditionally binding ADC targeting ROR2 was notably well tolerated The Company intends to meet with the FDA to discuss a SCCHN potential registrational trial in 2H 2024 SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today presented a poster of promising Phase 2 trial data at the European Society for Medical Oncology (ESMO) Annual Meeting. The poster presentation entitled, “Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck,” reported multiple confirmed responses among heavily pretreated patients who tolerated treatment well. The Company’s novel, conditionally active anti-ROR2-ADC was recently granted FDA Fast Track Designation for treatment of patients with recurrent or metastatic (R/M) SCCHN. “We continue to see promising antitumor activity associated with an excellent tolerability profile among heavily pretreated head and neck cancer patients with our CAB ROR2-ADC, ozuriftamab vedotin,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “Strikingly, we have observed an ongoing complete response and disease control rate of 77%, which underscores the CAB-ROR2-ADC’s activity in this difficult-to-treat population with profound unmet medical need. We remain on track to meet with the FDA later this year to discuss a potential randomized registrational trial evaluating ozuriftamab vedotin monotherapy versus investigator’s choice among patients with R/M SCCHN who have previously received platinum/PD-1 inhibitor agents.” In the Phase 2 clinical trial, inclusion criteria ...